LB PHARMACEUTICALS INC

LB Pharmaceuticals Inc. (Nasdaq: LBPH) is a late-stage biopharmaceutical company developing novel therapies for neuropsychiatric disorders. The company's website is www.lbpharm.com.

The company's lead product candidate, LB-102, is a patented small molecule in late-stage clinical development for the treatment of schizophrenia, bipolar depression, and adjunctive major depressive disorder. LB-102 is designed to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. The compound represents a methylated derivative of amisulpride, a second-generation antipsychotic approved in over 50 countries outside the United States. LB-102 was engineered to address amisulpride's limitations, including low blood-brain barrier permeability and high dosing requirements, while maintaining the parent compound's favorable clinical profile.

The company is advancing LB-102 through a Phase 3 clinical trial in acute schizophrenia, initiated in March 2026, with topline data expected in the second half of 2027. Concurrently, LB Pharmaceuticals is developing LB-102 in bipolar depression through a Phase 2 trial initiated in January 2026, with results anticipated in the first quarter of 2028. The company also plans to initiate a Phase 2 trial evaluating LB-102 as adjunctive therapy in major depressive disorder in early 2027. Additionally, the company is investigating long-acting injectable formulations of LB-102 to improve patient compliance and extend commercial protection.

LB Pharmaceuticals' strategy focuses on achieving regulatory approval for LB-102 in schizophrenia, expanding into mood disorders, and developing alternate formulations. The company owns global rights to LB-102 and intends to retain commercialization rights in the United States for approved indications. The U.S. antipsychotic market was valued at approximately twelve billion dollars as of 2024, with significant unmet medical needs remaining despite available therapeutics.

The company began trading on the Nasdaq Global Market on September 11, 2025, and is classified as a smaller reporting company and emerging growth company under Securities and Exchange Commission regulations.